摘要
目的观察吉西他滨联合顺铂治疗紫杉类及蒽环类耐药的晚期乳腺癌的疗效及不良反应。方法 32例晚期乳腺癌患者采用吉西他滨800～1000 mg/m2,静脉滴注30 min,d1,8;顺铂30 mg,d2～5。21 d为一周期,治疗2个周期以上后评价疗效及不良反应。结果 32例均可评价疗效,完全缓解（CR）2例,部分缓解（PR）13例,稳定（SD）9例,进展（PD）8例,总有效率（CR＋PR）46.88%,疾病控制率（CR＋PR＋SD）75.00%。主要不良反应为骨髓抑制、胃肠道反应。结论吉西他滨联合顺铂治疗晚期乳腺癌疗效较好,不良反应轻,耐受性好,是对耐药的晚期乳腺癌的有效治疗方案之一。
Objective To study the efficacy and toxic effects of gemcitabine combined with cisplatin in treatment of the anthracycline and taxane-resistant metastatic breast cancer.Methods Thirty two patients with advanced breast cancer were treated with gemcitabine 800-1000 mg/m2 on day1 and day8,cisplatin 30 mg on days 2-5.The chemotherapy repeated every 3 weeks.Efficacy and toxic reactions were reviewed after 2 cycles of chemotherapy.Results All patients were evaluable for response：CR 2 cases,PR 13 cases,SD 9 cases,and PD 8 cases.The overall response rate（ORR） was 46.88% and the disease control rate（DCR） was 75.0%.The main toxic reactions included myelosuppression and gastrointestinal reactions.Conclusion Gemcitabine combined with cisplatin is effective in the treatment of patients with advanced breast cancer,the toxic reaction is acceptable.It may be an effective regimen.
出处
《中华全科医学》
2011年第6期866-867,共2页
Chinese Journal of General Practice
关键词
吉西他滨
顺铂
乳腺癌
耐药
Gemcitabine
Cisplatin
Breast cancer
Drug resistance
